M3 Biotechnology is a clinical stage company with a novel platform of disease-modifying regenerative therapies particularly relevant to neurodegenerative diseases, with a focus on Alzheimer’s. M3’s lead asset, NDX-1017, modifies growth factor systems and is advanced as a first-in-class, disease-modifying treatment with the potential to restore lost connections between brain cells, turning degeneration into regeneration.
Oct. 20, 2017 14:40 UTC
--(BUSINESS WIRE)-- M3 Biotechnology is a clinical stage company with a novel platform of disease-modifying regenerative therapies particularly relevant to neurodegenerative diseases, with a focus on Alzheimer’s. M3’s lead asset, NDX-1017, modifies growth factor systems and is advanced as a first-in-class, disease-modifying treatment with the potential to restore lost connections between brain cells, turning degeneration into regeneration.
| Company: | M3 Biotechnology, Inc. | |
| Headquarters Address: | 4000 Mason Road | |
| Suite 300, Box 352141 | ||
| Seattle, WA 98195 | ||
| Main Telephone: | 206-221-8112 | |
| Website: | ||
| Type of Organization: | Private | |
| Industry: | Biotechnology | |
| Key Executives: | CEO: Leen Kawas | |
| Business Development | ||
| Contact: | Josh Pan | |
| Phone: | 206-616-2763 | |
| Email: |
View source version on businesswire.com: http://www.businesswire.com/news/home/20171020005008/en/
Source: M3 Biotechnology, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20171020005008/en
